Alzheimer's disease (AD) and cardiovascular disease (CVD) are strongly associated. Both
are multifactorial disorders with long asymptomatic phases and similar risk factors. Indeed …

Objectives Neurodevelopmental impairment has become the most important comorbidity in
infants with congenital heart disease (CHD). We aimed to (1) investigate the burden of brain …

Background Atherosclerosis has been linked to cognitive decline in late life; however, the
impact of cardiovascular risk factors (CVRFs) and subclinical atherosclerosis on brain …

Background Cardiovascular disease and dementia often coexist at advanced stages. Yet,
longitudinal studies examining the interplay between atherosclerosis and its risk factors on …

Brain glucose hypometabolism has been singled out as an important contributor and
possibly main trigger to Alzheimer's disease (AD). Intracerebroventricular injections of …

BACKGROUND: APOE is a known genetic contributor to cardiovascular disease, but the
differential role APOE alleles play in subclinical atherosclerosis remains unclear …

Coping with dementia requires an integrated approach encompassing personal, health,
research, and community domains. Here we describe “Walking the Talk for Dementia,” an …

Background Blood‐based biomarkers represent a promising tool for Alzheimer's disease
(AD) clinical diagnosis and patient management. However, the identification of physiological …

Background Amyloid‐β (Aβ) PET is commonly used for studying the earliest phases of
Alzheimer's disease (AD) in cognitively unimpaired (CU) individuals. In this group, the …

Impaired brain glucose consumption is a possible trigger of Alzheimer's disease (AD).
Animal models can help characterize each contributor to the cascade independently. Here …